(Q37915362)

25 August 2017

1 reference

title

A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer (English)

1 reference

25 August 2017

main subject

metastatic breast cancer

1 reference

Zoe Kemp

1

1 reference

25 August 2017

Alison Jones

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

8 August 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

28

1 reference

25 August 2017

issue

8

1 reference

25 August 2017

page(s)

603-614

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Historical perspective on hormonal therapy of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Letrozole in advanced breast cancer: the PO25 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0050-0

10.1007/S12325-011-0050-0

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference